Rating Change
HC Wainwright & Co. reiterated its Buy rating on Sagimet Biosciences Inc. (NASDAQ:SGMT) on October 05, 2026.
reiterateNASDAQ:SGMT
HC Wainwright & Co. Reiterates Buy Rating on Sagimet Biosciences Inc. (SGMT)
HC Wainwright & Co. reiterated its Buy rating on Sagimet Biosciences Inc.
At publication ·
What changed
Sagimet Biosciences Inc. (NASDAQ:SGMT) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $9.03
- Market capitalization
- $196.9M
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Sagimet Biosciences (SGMT) on October 5, 2026, with the stock trading at $9.03 and a market capitalization of $196.9 million.
Market Context
Sagimet Biosciences Inc. operates in the Healthcare sector. The stock currently trades at $9.03 with a market capitalization of $196.9M. The stock has gained 30.9% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Sagimet Biosciences Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Sagimet Biosciences Inc.
Among the 10 most recent ratings: 9 Buy, 0 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 05, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 02, 2026 | Guggenheim | Buy | N/A |
| Oct 01, 2026 | Oppenheimer | Outperform | N/A |
| Oct 01, 2026 | Citizens | Market Outperform | N/A |
| Sep 24, 2026 | Goldman Sachs | Sell | N/A |
Related Tools: Analyst Ratings Dashboard | View SGMT Stock Page
Frequently Asked Questions
What does the Buy rating mean for SGMT?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Sagimet Biosciences Inc. (NASDAQ:SGMT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the SGMT forecast page.